W E Evans

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. pmc Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells
    Barthélémy Diouf
    Hematological Malignancies Program, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Nat Med 17:1298-303. 2011
  2. pmc A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm
    W E Evans
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 94:224-9. 2013
  3. ncbi request reprint Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way
    William E Evans
    St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pharmacogenetics 12:421-3. 2002
  4. ncbi request reprint Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine
    W E Evans
    St Jude Children s Research Hospital and University of Tennessee, Memphis 38101 0318, USA
    J Clin Oncol 19:2293-301. 2001
  5. ncbi request reprint Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy
    William E Evans
    St Jude Children s Research Hospital and University of Tennessee Health Sciences Center, Memphis, TN 38101 0318, USA
    Ther Drug Monit 26:186-91. 2004
  6. pmc Pharmacogenomics: marshalling the human genome to individualise drug therapy
    W E Evans
    St Jude Children s Research Hospital, Memphis, TN 38101 0318, USA
    Gut 52:ii10-8. 2003
  7. ncbi request reprint Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis
    William E Evans
    St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pharmacogenetics 12:181-2. 2002
  8. ncbi request reprint Pharmacogenomics: the inherited basis for interindividual differences in drug response
    W E Evans
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Annu Rev Genomics Hum Genet 2:9-39. 2001
  9. ncbi request reprint Expression arrays illuminate a way forward for mantle cell lymphoma
    William E Evans
    Department of Pharmaceutical Science, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer Cell 3:100-2. 2003
  10. ncbi request reprint Moving towards individualized medicine with pharmacogenomics
    William E Evans
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Nature 429:464-8. 2004

Collaborators

Detail Information

Publications119 found, 100 shown here

  1. pmc Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells
    Barthélémy Diouf
    Hematological Malignancies Program, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Nat Med 17:1298-303. 2011
    ..These findings reveal a previously unrecognized mechanism whereby somatic deletions of genes regulating MSH2 degradation result in undetectable levels of MSH2 protein in leukemia cells, DNA mismatch repair deficiency and drug resistance...
  2. pmc A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm
    W E Evans
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 94:224-9. 2013
    ..Here, we illustrate how genomics has been deployed to advance the treatment of childhood leukemia. ..
  3. ncbi request reprint Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way
    William E Evans
    St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pharmacogenetics 12:421-3. 2002
  4. ncbi request reprint Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine
    W E Evans
    St Jude Children s Research Hospital and University of Tennessee, Memphis 38101 0318, USA
    J Clin Oncol 19:2293-301. 2001
    ..To assess thiopurine S-methyltransferase (TPMT) phenotype and genotype in patients who were intolerant to treatment with mercaptopurine (MP) or azathioprine (AZA), and to evaluate their clinical management...
  5. ncbi request reprint Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy
    William E Evans
    St Jude Children s Research Hospital and University of Tennessee Health Sciences Center, Memphis, TN 38101 0318, USA
    Ther Drug Monit 26:186-91. 2004
    ....
  6. pmc Pharmacogenomics: marshalling the human genome to individualise drug therapy
    W E Evans
    St Jude Children s Research Hospital, Memphis, TN 38101 0318, USA
    Gut 52:ii10-8. 2003
    ..It seems that this field is at the early stages of developing a powerful set of molecular diagnostics that will have profound utility in optimising drug therapy for individual patients...
  7. ncbi request reprint Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis
    William E Evans
    St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pharmacogenetics 12:181-2. 2002
  8. ncbi request reprint Pharmacogenomics: the inherited basis for interindividual differences in drug response
    W E Evans
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Annu Rev Genomics Hum Genet 2:9-39. 2001
    ..This chapter provides an overview of the current pharmacogenomics literature and offers insights for the potential impact of this field on the safe and effective use of medications...
  9. ncbi request reprint Expression arrays illuminate a way forward for mantle cell lymphoma
    William E Evans
    Department of Pharmaceutical Science, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer Cell 3:100-2. 2003
  10. ncbi request reprint Moving towards individualized medicine with pharmacogenomics
    William E Evans
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Nature 429:464-8. 2004
    ..This intersection of genomics and medicine has the potential to yield a new set of molecular diagnostic tools that can be used to individualize and optimize drug therapy...
  11. ncbi request reprint Pharmacogenomics--drug disposition, drug targets, and side effects
    William E Evans
    St Jude Children s Research Hospital and the University of Tennessee Colleges of Pharmacy and Medicine, Memphis 38101 0318, USA
    N Engl J Med 348:538-49. 2003
  12. pmc Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia
    C H Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 24:371-82. 2010
    ..The next main challenge is to further increase cure rates while improving quality of life for all patients...
  13. ncbi request reprint Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
    M V Relling
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Natl Cancer Inst 91:2001-8. 1999
    ..We studied the metabolism, dose requirements, and tolerance of 6-mercaptopurine among patients with different TPMT phenotypes...
  14. ncbi request reprint Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance
    C R Yates
    St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Ann Intern Med 126:608-14. 1997
    ....
  15. ncbi request reprint Polymorphism of the thiopurine S-methyltransferase gene in African-Americans
    Y Y Hon
    Pharmaceutical and Hematology Oncology Departments, St Jude Children s Research Hospital, 332 North Lauderdale, PO Box 318, Memphis, TN 38101 0318, USA
    Hum Mol Genet 8:371-6. 1999
    ..These data indicate that the same TPMT mutant alleles are found in American black and white populations, but that the predominant mutant alleles differ in these two ethnic groups...
  16. pmc Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity
    S H Chen
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 88:191-6. 2010
    ..05) in both cohorts. Chromosome 5q33 has previously been associated with asthma and atopy. These data contribute to the growing body of evidence that there is an inherited component to predisposition to drug allergy...
  17. pmc Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1
    S Jeha
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:1406-9. 2009
    ..These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse...
  18. pmc Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity
    H L Tai
    St Jude Children s Research Hospital, 332 North Lauderdale Street, Memphis, TN 38101, USA
    Proc Natl Acad Sci U S A 94:6444-9. 1997
    ..These studies establish enhanced degradation of TPMT proteins encoded by TPMT*2 and TPMT*3A as mechanisms for lower TPMT protein and catalytic activity inherited by the predominant mutant alleles at the human TPMT locus...
  19. ncbi request reprint Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms
    E Y Krynetski
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Pharmacogenetics 6:279-90. 1996
    ..Together, these advances bold the promise of improving the safety and efficacy of thiopurine therapy...
  20. ncbi request reprint Late effects of treatment in survivors of childhood acute myeloid leukemia
    W Leung
    After Completion of Therapy Program, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 18:3273-9. 2000
    ..To investigate the incidence of and risk factors for late sequelae of treatment in patients who survived for more than 10 years after the diagnosis of childhood acute myeloid leukemia (AML)...
  21. ncbi request reprint Pharmacogenomics: translating functional genomics into rational therapeutics
    W E Evans
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Science 286:487-91. 1999
    ....
  22. ncbi request reprint Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia
    M V Relling
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet 356:285-90. 2000
    ..Most anticonvulsant drugs induce drug-metabolising enzymes and thereby increase the clearance of anticancer agents. We investigated whether anticonvulsants compromise the efficacy of cancer chemotherapy...
  23. pmc Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia
    G Stocco
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 85:164-72. 2009
    ....
  24. ncbi request reprint Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia
    A Gajjar
    Departments of Hematology Oncology, Biostatistics and Epidemiology, Pharmaceutical Sciences, and Pathology, St Jude Children s Research Hospital, Memphis, TN, USA
    Blood 96:3381-4. 2000
    ..These data indicate that contamination of CSF with circulating leukemic blast cells during diagnostic lumbar puncture can adversely affect the treatment outcome of children with ALL and is an indication to intensify intrathecal therapy...
  25. ncbi request reprint Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library
    E Y Krynetski
    Dept of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38101, USA
    Pharm Res 14:1672-8. 1997
    ..To isolate and characterize the polymorphic human thiopurine S-methyltransferase (TPMT) gene...
  26. ncbi request reprint Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia
    C H Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 16:3768-73. 1998
    ..To reassess the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia (ALL)...
  27. ncbi request reprint Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia
    Sanne Lugthart
    Hematological Malignancy Program, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer Cell 7:375-86. 2005
    ..The expression of these genes discriminated treatment outcome in two independent patient populations, identifying a subset of patients with a markedly inferior outcome (37% +/- 13% 5 year DFS)...
  28. pmc Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia
    Jun J Yang
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    JAMA 301:393-403. 2009
    ..Pediatric acute lymphoblastic leukemia (ALL) is the prototype for a drug-responsive malignancy. Although cure rates exceed 80%, considerable unexplained interindividual variability exists in treatment response...
  29. ncbi request reprint A novel protein complex distinct from mismatch repair binds thioguanylated DNA
    E Y Krynetski
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38163, USA
    Mol Pharmacol 59:367-74. 2001
    ....
  30. pmc A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity
    S H Chen
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 25:66-74. 2011
    ..5 × 10(-5)). Our genome-wide interrogation of CEU cell lines and primary ALL blasts revealed that inherited genomic interindividual variation in a plausible candidate pathway can contribute to asparaginase sensitivity...
  31. pmc Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians
    H L Tai
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Am J Hum Genet 58:694-702. 1996
    ....
  32. pmc Pharmacogenetics of outcome in children with acute lymphoblastic leukemia
    Jose Claudio C Rocha
    Department of Pharmaceutical Sciences, Saint Jude Children s Research Hospital of the University of Tennessee, Memphis 38105 2794, USA
    Blood 105:4752-8. 2005
    ..04). The GSTM1 non-null and TYMS 3/3 genotypes are plausibly linked to drug resistance. Polymorphisms interact to influence antileukemic outcome and represent determinants of response that can be used to optimize therapy...
  33. pmc Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia
    C Liu
    Department of Pharmaceutical Sciences, Memphis, TN, USA
    Leukemia 26:2303-9. 2012
    ..83; 95% confidence interval, 0.78-0.89; P=0.007). Antibodies were related to clinical allergy and to low systemic exposure to asparaginase, leading to lower risk of some adverse effects of therapy...
  34. pmc ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy
    D Bhojwani
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 26:265-70. 2012
    ....
  35. pmc Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing
    M V Relling
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 89:387-91. 2011
    ..We provide dosing recommendations (updates at http://www.pharmgkb.org) for azathioprine, mercaptopurine (MP), and thioguanine based on TPMT genotype...
  36. ncbi request reprint Second malignancy after treatment of childhood non-Hodgkin lymphoma
    W Leung
    St Jude Children s Research Hospital, 332 N Lauderdale Street, Memphis, TN 38105 2794, USA
    Cancer 92:1959-66. 2001
    ....
  37. ncbi request reprint Molecular cloning and functional characterization of the cDNA encoding the murine thiopurine S-methyltransferase (TPMT)
    M Y Fessing
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    FEBS Lett 424:143-5. 1998
    ..The expression product of the murine cDNA in rabbit reticulocyte and wheat germ lysate coupled transcription-translation systems showed TPMT enzymatic activity. We conclude that the isolated cDNA clone represents the murine TPMT cDNA...
  38. ncbi request reprint Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug
    N F Krynetskaia
    St. Jude Children's Research Hospital, 332 N. Lauderdale St, Memphis, TN 38105, USA
    FASEB J 15:1902-8. 2001
    ..Thus, thiopurines are novel anti-retroviral agents that alter the DNA-RNA substrates for HIV RNaseH, thereby abrogating early stages of HIV replication...
  39. pmc Pharmacogenomics and individualized medicine: translating science into practice
    K R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 92:467-75. 2012
    ....
  40. ncbi request reprint Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism
    T S Jones
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, and College of Pharmacy, University of Tennessee, Memphis, TN, USA
    Clin Pharmacol Ther 81:729-34. 2007
    ..Our findings show that HapMap resources are useful for pharmacogenetic discovery when the candidate gene is known, but challenges remain for definitive gene identification when a genome-wide agnostic approach is employed...
  41. pmc Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia
    Deborah French
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 113:4512-20. 2009
    ..We conclude that acquired genetic variation in leukemia cells has a stronger influence on MTXPG accumulation than inherited genetic variation...
  42. pmc Germline genomic variants associated with childhood acute lymphoblastic leukemia
    Lisa R Treviño
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Nat Genet 41:1001-5. 2009
    ..86, respectively) and were associated with methotrexate accumulation and gene expression pattern in leukemic lymphoblasts. We conclude that germline variants affect susceptibility to, and characteristics of, specific ALL subtypes...
  43. pmc Concordance of DMET plus genotyping results with those of orthogonal genotyping methods
    C A Fernandez
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 92:360-5. 2012
    ..96%. We conclude that the DMET Plus array performs well with primary patient samples, with the results in good concordance with those of several lower-throughput genotyping methods...
  44. ncbi request reprint Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells
    Meyling H Cheok
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, Tennessee 38105 USA
    Nat Genet 34:85-90. 2003
    ....
  45. pmc Ancestry and pharmacogenetics of antileukemic drug toxicity
    Shinji Kishi
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 109:4151-7. 2007
    ..026). The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers. Germ-line polymorphisms are significant determinants of toxicity of antileukemic therapy...
  46. pmc Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects
    Lisa R Treviño
    St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 27:5972-8. 2009
    ..Our aim was to identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (ALL)...
  47. ncbi request reprint Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements
    C H Pui
    St Jude Chidren s Research Hospital and University of Tennessee, Memphis, 38105, USA
    Leukemia 17:700-6. 2003
    ....
  48. pmc The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer
    J J Yang
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 94:252-9. 2013
    ..In conclusion, our results indicated that TPMT or COMT genetic variation was not related to cisplatin ototoxicity in children with cancer and did not influence cisplatin-induced hearing damage in laboratory models. ..
  49. ncbi request reprint Second malignancy after treatment of childhood acute myeloid leukemia
    W Leung
    Department of Hematology-Oncology, St Jude Children's Research Hospital, and University of Tennessee, College of Medicine, Memphis, USA
    Leukemia 15:41-5. 2001
    ..Future studies should focus on improving treatments for primary AML while preventing second malignancies...
  50. pmc Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells
    J C Panetta
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 North Lauderdale St, Memphis, TN 38105, USA
    Br J Cancer 94:93-100. 2006
    ..In summary, the mathematical model provides a quantitative assessment to compare the cell cycle effects of MP in cells with varying degrees of MP resistance...
  51. ncbi request reprint Childhood acute lymphoblastic leukaemia--current status and future perspectives
    C H Pui
    Leukaemia Lymphoma Division, Fahad Nassar Al Rashid Chair of Leukaemia Research at St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet Oncol 2:597-607. 2001
    ..Ultimately, treatment based on biological features of leukaemic cells, host genetics, and the amount of residual disease should improve cure rates further...
  52. pmc Improved prognosis for older adolescents with acute lymphoblastic leukemia
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:386-91. 2011
    ..We reviewed the outcome of older adolescents (age 15 to 18 years) treated in four consecutive Total Therapy studies to determine if recent improved treatment extended to this high-risk group...
  53. ncbi request reprint Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:7936-41. 2005
    ..Our goal was to use the information to further refine therapy and advance cure rates...
  54. ncbi request reprint Pharmacogenomics of acute leukemia
    Meyling H Cheok
    St Jude Children s Research Hospital, Department of Pharmaceutical Sciences, Memphis, TN 38105, USA
    Annu Rev Pharmacol Toxicol 46:317-53. 2006
    ..These strategies illustrate the promise of pharmacogenomics to further advance the treatment of human cancers, with childhood leukemia serving as a paradigm...
  55. ncbi request reprint Treatment of acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology and Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    N Engl J Med 354:166-78. 2006
  56. ncbi request reprint Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy
    Meyling H Cheok
    St Jude Children s Research Hospital, Department of Pharmaceutical Sciences, 332 North Lauderdale Street, Memphis, Tennessee 38105, USA
    Nat Rev Cancer 6:117-29. 2006
    ..Germline polymorphisms and gene-expression patterns in ALL cells have been linked to the toxicity and efficacy of chemotherapy for ALL and are beginning to emerge as useful clinical diagnostics...
  57. ncbi request reprint Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?
    Ching Hon Pui
    Departments of Oncology and Pharmaceutical Sciences, St Jude Children s Research Hospital, and Colleges of Medicine and Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38105, USA
    Leuk Lymphoma 47:2431-2. 2006
  58. doi request reprint Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status
    Gabriele Stocco
    St Jude Children s Research Hospital, Department of Pharmaceutical Sciences, 262 Danny Thomas Place MS 272, Memphis, TN 38105, USA
    Expert Opin Drug Saf 9:23-37. 2010
    ....
  59. pmc Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing
    Stan Pounds
    Department of Biostatistics, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Int J Data Min Bioinform 5:143-57. 2011
    ..In the analysis of a paediatric leukaemia data set, PROMISE effectively identifies genomic features that exhibit a biologically meaningful pattern of association with multiple endpoint variables...
  60. pmc Treating childhood acute lymphoblastic leukemia without cranial irradiation
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 360:2730-41. 2009
    ..Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse...
  61. ncbi request reprint Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 297:1207-15. 2007
    ..Little is known about the incidence of secondary neoplasms after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic leukemia...
  62. pmc Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells
    John C Panetta
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, United States of America
    PLoS Comput Biol 6:e1001019. 2010
    ..This study has provided new insights into the intracellular disposition of MTX in leukemia cells and how it affects treatment efficacy...
  63. ncbi request reprint Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment
    Mary V Relling
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 101:3862-7. 2003
    ..Even when children receiving irradiation were excluded, the incidence was still higher in those receiving G-CSF (P =.019). In the setting of intensive antileukemic therapy, short-term use of G-CSF may increase the risk of t-ML...
  64. ncbi request reprint Results of therapy for acute lymphoblastic leukemia in black and white children
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 290:2001-7. 2003
    ..Treatment results for acute lymphoblastic leukemia (ALL) clearly have improved over the past decade, but black children have not fared as well as white children in large national trials...
  65. ncbi request reprint Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 104:2690-6. 2004
    ..01% or more at the end of the 6-week remission induction phase. Our results suggest the efficacy of early intensification of intrathecal chemotherapy and provide the basis for studies omitting cranial irradiation altogether...
  66. ncbi request reprint Childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, and Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA
    Rev Clin Exp Hematol 6:161-80; discussion 200-2. 2002
    ..In the interim, prospective clinical trials have provided valuable clues that are further increasing the cure rate of childhood acute lymphoblastic leukemia...
  67. ncbi request reprint Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia
    Wing Leung
    After Completion of Therapy Program and the Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 20:2959-64. 2002
    ..We investigated the adult height of patients who had received GH and estimated their risk of leukemia relapse or development of a second malignancy...
  68. ncbi request reprint Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia
    Gaston K Rivera
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 103:368-76. 2005
    ..The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy...
  69. ncbi request reprint Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 349:640-9. 2003
    ..We determined the long-term survival and the rates of health insurance coverage, marriage, and employment among patients who had attained at least 10 years of event-free survival...
  70. ncbi request reprint Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children
    W E Evans
    Pharmacokinetics and Pharmacodynamics Section, St Jude Children s Research Hospital, Memphis, TN 38101 0318
    Clin Pharmacol Ther 45:568-73. 1989
    ....
  71. ncbi request reprint Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop
    C H Pui
    St Jude Children s Research Hospital, Memphis, TN, USA
    Leukemia 18:1043-53. 2004
  72. ncbi request reprint Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia
    C H Pui
    Dept of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Ann Hematol 83:S124-6. 2004
    ....
  73. pmc A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase
    E Y Krynetski
    Pharmaceutical Department, St Jude Children s Research Hospital, Memphis, TN 38105
    Proc Natl Acad Sci U S A 92:949-53. 1995
    ..This inactivating mutation in the human TPMT gene provides insights into the genetic basis for this inherited polymorphism in drug metabolism...
  74. pmc In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile
    Michael J Sorich
    Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, United States of America
    PLoS Med 5:e83. 2008
    ..Therefore, we measured the in vivo antileukemic effects of MTX and identified genes whose expression differed significantly in patients with a good versus poor response to MTX...
  75. ncbi request reprint Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia
    Ching Hon Pui
    St Jude Children s Research Hospital, and the Colleges of Medicine and Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    Best Pract Res Clin Haematol 15:741-56. 2002
    ..Increasingly, pharmacodynamic and pharmacogenomic studies are being used to individualize therapy to enhance efficacy and reduce toxicity...
  76. pmc Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia
    Jun J Yang
    St Jude Children s Research Hospital, Memphis, TN, USA
    Blood 112:4178-83. 2008
    ....
  77. ncbi request reprint A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia
    John Carl Panetta
    St Jude Children s Research Hospital, 332 North Lauderdale St, Memphis, TN 38105 2794, USA
    Cancer Chemother Pharmacol 50:419-28. 2002
    ..These differences provide mechanistic and treatment insights for lineage and ploidy differences in MTXPG accumulation in human leukemia cells in vivo...
  78. ncbi request reprint Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation
    Oliver G McDonald
    St Jude Children s Research Hospital, Memphis, TN 38101 0318, USA
    Pharmacogenetics 12:93-9. 2002
    ....
  79. pmc Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment
    Gianluigi Zaza
    St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Blood 106:1778-85. 2005
    ....
  80. ncbi request reprint Closing the gap between science and clinical practice: the thiopurine S-methyltransferase polymorphism moves forward
    Eugene Y Krynetskiy
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pharmacogenetics 14:395-6. 2004
  81. ncbi request reprint Drug methylation in cancer therapy: lessons from the TPMT polymorphism
    Eugene Krynetski
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Oncogene 22:7403-13. 2003
    ..Insights gained from studies of the TPMT polymorphism illustrate the potential of pharmacogenomics to optimize cancer therapy by avoiding toxic side effects in genetically distinct subgroups of patients...
  82. ncbi request reprint De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo
    Thierry Dervieux
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital and University of Tennessee, Memphis, 38105, USA
    Blood 100:1240-7. 2002
    ....
  83. ncbi request reprint Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics
    Christine Hartford
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, University of Tennessee, Memphis, Tennessee, USA
    Cancer Res 67:4965-72. 2007
    ....
  84. pmc Ligation of CD38 suppresses human B lymphopoiesis
    M Kumagai
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38101
    J Exp Med 181:1101-10. 1995
    ....
  85. ncbi request reprint Comprehensive assessment of thiopurine S-methyltransferase (TPMT) alleles in three ethnic populations
    William E Evans
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    J Pediatr Hematol Oncol 24:335-6. 2002
  86. ncbi request reprint Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
    Eng Juh Yeoh
    Department of Pathology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer Cell 1:133-43. 2002
    ..Thus, the single platform of expression profiling should enhance the accurate risk stratification of pediatric ALL patients...
  87. pmc Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs
    Deborah French
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, United States of America
    PLoS ONE 3:e2144. 2008
    ....
  88. ncbi request reprint Lymphoid gene expression as a predictor of risk of secondary brain tumors
    Mathew J Edick
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, University of Tennessee, Memphis, Tennessee, USA
    Genes Chromosomes Cancer 42:107-16. 2005
    ..These data suggest that gene expression profiling from accessible tissues may identify targets involved in therapy-related malignancies in unrelated tissues...
  89. ncbi request reprint Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes
    Qing Cheng
    Hematological Malignancies Program, Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, Tennessee 38105, USA
    Nat Genet 37:878-82. 2005
    ..Therefore, chromosomal gain can alter the concordance of germline genotype and cancer cell phenotypes, indicating that allele-specific quantitative genotyping may be required to define cancer pharmacogenomics unequivocally...
  90. ncbi request reprint Global gene expression as a function of germline genetic variation
    Deborah French
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Hum Mol Genet 14:1621-9. 2005
    ....
  91. ncbi request reprint Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis
    Gianluigi Zaza
    St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Blood 104:1435-41. 2004
    ..These findings have established that TEL-AML1 ALL has significantly lower de novo purine synthesis and differential expression of genes involved in purine metabolism...
  92. ncbi request reprint Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity
    John Carl Panetta
    Departments of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Clin Cancer Res 8:2423-9. 2002
    ..Together, these findings provide new insights to the intracellular disposition of MTX in human ALL cells, and provides a mechanism-based model for characterizing differences among patients and genetic subtypes of ALL...
  93. ncbi request reprint A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells
    Qing Cheng
    Department of Pharmaceutical Sciences, Hematological Malignancies Program, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pharmacogenetics 14:557-67. 2004
    ..These studies demonstrate a substrate specific functional SNP (452C>T) in the human GGH gene that is associated with lower catalytic activity and higher accumulation of long-chain MTX-PG in leukaemia cells of patients treated with HDMTX...
  94. pmc Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics
    Leo Kager
    Hematological Malignancies Program, and Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Clin Invest 115:110-7. 2005
    ..These findings reveal distinct mechanisms of subtype-specific differences in MTXPG accumulation and point to new strategies to overcome these potential causes of treatment failure in childhood ALL...
  95. ncbi request reprint Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia
    Thierry Dervieux
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Clin Pharmacol Ther 73:506-16. 2003
    ..Methotrexate is postulated to enhance mercaptopurine activation to thioguanine (INN, tioguanine) nucleotides, but the interaction has never been studied in vivo in cancer cells...
  96. ncbi request reprint Cancer pharmacogenomics may require both qualitative and quantitative approaches
    Qing Cheng
    Hematological Malignancies Program, Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennesee 38105, USA
    Cell Cycle 4:1506-9. 2005
    ..Results of recent studies indicate that both qualitative and quantitative genomic analyses may be required for precise pharmacogenomic characterization of some types of human cancer...
  97. ncbi request reprint Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression
    Nicolas Pottier
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Hum Mol Genet 16:2261-71. 2007
    ..In summary, we provide functional evidence that SMARCB1 is involved in prednisolone resistance and identified a promoter SNP that alters the level of SMARCB1 mRNA and protein expression and the binding of PARP1 to the SMARCB1 promoter...
  98. pmc Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial
    Torben S Mikkelsen
    St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105, USA
    J Clin Oncol 29:1771-8. 2011
    ....
  99. ncbi request reprint Creating an infrastructure for pediatric oncology drug development
    William E Evans
    St Jude Children s Research Hospital, Memphis, TN, USA
    Clin Adv Hematol Oncol 5:198-200. 2007
  100. pmc Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells
    Qing Cheng
    Hematological Malignancies Program, Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Am J Hum Genet 79:264-74. 2006
    ....
  101. ncbi request reprint Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice
    Natalia F Krynetskaia
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Mol Pharmacol 64:456-65. 2003
    ..Together, these findings establish that hematopoietic toxicity in vivo after treatment with mercaptopurine is attenuated but not abolished by MSH2 deficiency...